A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

ConditionsAtherosclerosis Cardiovascular Disease Chronic Kidney Disease

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age50+

SponsorEli Lilly and Company

About this trial

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility criteria

Qualifiers

Have established ASCVD and/or CKD

Disqualifiers

Have type 1 diabetes

Have had a major heart condition within 60 days prior to screening

Have New York Heart Association Functional Classification Class IV heart failure

Trial design

Treatments tested in this trial

Orforglipron
Placebo

Treatment groups

7,140 Participants

are divided into 2 treatment groups

Locations

568

Argentina

Instituto de Investigaciones Clínicas Bahia Blanca8000, Bahía Blanca Argentina

Buenos Aires Macula S.A1061, Buenos Aires Argentina

Cardiología Palermo1425, Buenos Aires Argentina

CEMEDICC1407GTN, Buenos Aires Argentina

Sponsors and collaborators

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov